Mosby's 2014 Nursing Drug Reference (426 page)

BOOK: Mosby's 2014 Nursing Drug Reference
13.22Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

zinc (Rx, otc)

Galzin

Func. class.:
Trace element; nutritional supplement

ACTION:

Needed for adequate healing, bone and joint development (23% zinc)

USES:

Prevention of zinc deficiency, adjunct to vit A therapy

Unlabeled uses:
Wound healing

Precautions:
Pregnancy (C) parenteral; breastfeeding, neonates, hypocupremia, neonatal prematurity, renal disease

DOSAGE AND ROUTES
Calculator
Dietary supplement (elemental zinc)

• Adult/adolescent/pregnant female:
PO
11-13 mg/day

• Adult/lactating female:
PO
12-14 mg/day × 12 mo

• Adult/adolescent male ≥14 yr:
PO
11 mg/day

• Adult female ≥19 yr:
PO
8 mg/day

• Adolescent female ≥14 yr:
PO
9 mg/day

• Child 9-13 yr:
PO
8 mg/day

• Child 4-8 yr:
PO
5 mg/day

• Child 1-3 yr:
PO
3 mg/day

• Infant 7-12 mo:
PO
3 mg/day

• Infant birth to 6 mo:
PO
2 mg/day (adequate intake)

Nutritional supplement (IV)

• Adult:
IV
2.5-4 mg/day; may increase by 2 mg/day if needed

• Child 1-5 yr:
IV
50 mcg/kg/day

Wound healing

• Adult:
PO
50 mg tid until healed (elemental zinc)

Available forms:
Tabs 66, 110 mg; caps 220 mg; inj 1 mg, 5 mg/ml

Administer:

• 
With meals to decrease gastric upset; avoid dairy products

SIDE EFFECTS

GI:
Nausea, vomiting, cramps, heartburn, ulcer formation

OVERDOSE:
Diarrhea, rash, dehydration, restlessness

INTERACTIONS

Decrease:
absorption of fluoroquinolones—tetracyclines

Drug/Food

Decrease:
absorption of PO zinc—dairy products, caffeine

NURSING CONSIDERATIONS
Assess:

• 
Zinc deficiency:
poor wound healing, absence of taste, smell, slowing growth

• 
Alkaline phosphatase, HDL monthly in long term therapy

• 
Zinc levels during treatment

Evaluate:

• 
Therapeutic response: absence of zinc deficiency

Teach patient/family:

• 
That element must be taken for 2-3 mo to be effective

• 
To immediately report nausea, diarrhea, rash, severe vomiting, restlessness, abdominal pain, tarry stools

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ziprasidone (Rx)

(zi-praz′ih-dohn)

Geodon, Zeldox

Func. class.:
Antipsychotic/neuroleptic

Chem. class.:
Benzisoxazole derivative

ACTION:

Unknown; may be mediated through both dopamine type 2 (D
2
) and serotonin type 2 (5-HT
2
) antagonism

USES:

Schizophrenia, acute agitation, acute psychosis, bipolar disorder, mania, psychotic depression

Unlabeled uses:
Tourette’s syndrome

CONTRAINDICATIONS:

Breastfeeding, hypersensitivity, acute MI, heart failure, QT prolongation

Precautions:
Pregnancy (C), children, geriatric patients, cardiac/renal/hepatic disease, breast cancer, diabetes, seizure disorders, AV block, CNS depression

 

Black Box Warning:

Increased mortality in geriatric patients with dementia-related psychosis

DOSAGE AND ROUTES
Calculator
Schizophrenia

• Adult:
PO
20 mg bid with food, adjust dosage every 2 days upward to max of 80 mg bid;
IM
10-20 mg; may give 10 mg q2hr; doses of 20 mg may be given q4hr; max 40 mg/day (acute episodes); switch to PO as soon as possible

Bipolar disorder

• Adult:
PO
40 mg bid with food; on day 2 increase to 60 or 80 mg bid, then adjust to response; maintenance as adjunct to lithium/valproate 40-80 mg bid

Tourette’s syndrome (unlabeled)

• Adolescent and child ≥7 yr:
PO
5 mg/day, may increase in divided doses to 20 mg bid

Available forms:
Caps 20, 40, 60, 80 mg; inj 20 mg/ml single-dose vials

Administer:
PO route

• 
Reduced dose in geriatric patients

• 
Anticholinergic agent on order from prescriber to be used for EPS

IM route

• 
Add 1.2 ml sterile water for inj to vial; shake vigorously until dissolved; do not admix; give only IM

SIDE EFFECTS

CNS:
EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia; drowsiness, insomnia, agitation, anxiety, headache
,
seizures, neuroleptic malignant syndrome,
dizziness, tremor, facial droop

CV:
Orthostatic hypotension,
tachycardia, prolonged QT/QTc,
hypertension;
sudden death, heart failure (geriatric patients), torsades de pointes

EENT:
Blurred vision, diplopia

ENDO:
Metabolic changes

GI:
Nausea
, vomiting,
anorexia, constipation
, jaundice, weight gain, diarrhea, dry mouth, abdominal pain

GU:
Enuresis, urinary incontinence, gynecomastia, impotence, priapism

RESP:
Rhinitis, dyspnea, infection, cough

PHARMACOKINETICS

PO:
Extensively metabolized by liver to major active metabolite, plasma protein binding 90%, peak 6-8 hr, terminal half-life 7 hr

INTERACTIONS

 
Increase:
QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine, moxifloxacin

Increase:
sedation—other CNS depressants, alcohol

Increase:
EPS, possible neurotoxicity—other antipsychotics, lithium

Increase:
ziprasidone excretion—carBAMazepine

Increase:
ziprasidone level—ketoconazole

Increase:
hypotension—antihypertensives

Increase:
serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs

NURSING CONSIDERATIONS
Assess:

• 
Mental status before initial administration

 

Black Box Warning:

Geriatric patient with dementia closely; heart failure, sudden death have occurred

• 
Bilirubin, CBC, LFTs, fasting blood glucose monthly

• 
Urinalysis before, during prolonged therapy

• 
B/P standing and lying; also pulse, respirations; take these q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes; QT prolongation may occur

• 
Dizziness, faintness, palpitations, tachycardia on rising; metabolic changes, weight gain

• 
EPS,
including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of
the jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)

 
Neuroleptic malignant syndrome, serotonin syndrome:
hyperthermia, increased CPK, altered mental status, muscle rigidity

• 
Constipation, urinary retention daily; if these occur, increase bulk and water in diet

Perform/provide:

• 
Supervised ambulation until patient is stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for a long time

• 
Increased fluids to prevent constipation

• 
Storage in tight, light-resistant container

Evaluate:

• 
Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech

Teach patient/family:

• 
That orthostatic hypotension may occur; to rise from sitting or lying position gradually

• 
To avoid hot tubs, hot showers, tub baths because hypotension may occur

• 
To avoid abrupt withdrawal of product because EPS may result; that product should be withdrawn slowly

• 
To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber because serious product interactions may occur; to avoid use with alcohol because increased drowsiness may occur

• 
To avoid hazardous activities if drowsy or dizzy

• 
To report impaired vision, tremors, muscle twitching

• 
In hot weather, that heat stroke may occur; to take extra precautions to stay cool

TREATMENT OF OVERDOSE:

Lavage if orally ingested; provide airway;
do not induce vomiting

Other books

The White-Luck Warrior by R. Scott Bakker
A Man in a Distant Field by Theresa Kishkan
Strange Light Afar by Rui Umezawa
2009 - Ordinary Thunderstorms by William Boyd, Prefers to remain anonymous
Rise and Fall by Kelleher, Casey
Justice for All by Jim Newton
Malice in London by Graham Thomas
Fighting Terrorism by Benjamin Netanyahu
Blue Lantern by Gil Hogg